FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Moderna's Trailing 12-Month Free Cash Flow is €-1,387 Mil, and Market Cap is €23,494 Mil. Therefore, Moderna's FCF Yield % for today is -6.01%.
The historical rank and industry rank for Moderna's FCF Yield % or its related term are showing as below:
CHIX:0QFd'
s FCF Yield % Range Over the Past 10 Years
Min: -43.1 Med: -6.09 Max: 24.06
Current: -6.01
During the past 10 years, the highest FCF Yield % of Moderna was 24.06%. The lowest was -43.10%. And the median was -6.09%.
CHIX:0QFd's FCF Yield % is ranked better than 57.4% of 1418
companies
in the Biotechnology industry
Industry Median: -9.715
vs CHIX:0QFd: -6.01
Moderna's FCF Margin % for the quarter that ended in Mar. 2026 was -177.89%.
Moderna FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Moderna FCF Yield % Related Terms
Moderna FCF Yield % Historical Data
* Premium members only.
The historical data trend for Moderna's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:0QFD vs INCY, ROIV, JAZZ: FCF Yield % Comparison
For the Biotechnology subindustry, Moderna's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Moderna's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (CHIX:0QFD) has a FCF Yield % of -6.01 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Moderna and its competitors. According to the industry distribution chart, Moderna ranks #604 out of 1418 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Moderna's FCF Yield % too high?
Moderna's current FCF Yield % is -6.01. Based on the distribution chart, Moderna ranks #604 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moderna has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's FCF Yield % compare to INCY and ROIV?
According to the Biotechnology industry distribution chart, Moderna ranks #604 out of 1418 companies for FCF Yield %. This puts Moderna in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Moderna and its competitors. Moderna's current FCF Yield % is -6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (CHIX:0QFD) has a current FCF Yield % of -6.01. The stock's GF Value™ is €14.56, compared to a current price of €42.71 — trading 193.3% above its estimated fair value. The current FCF Yield % is -6.01. Moderna's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current FCF Yield % is -6.01 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (CHIX:0QFD) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of €42.71 is trading 193.3% above its estimated GF Value™ of €14.56.
Key valuation signals for CHIX:0QFD:
FCF Yield %: -6.01
GF Value™: €14.56 vs. price of €42.71 (193.3% above fair value)
No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
58GF Score
Get the complete analysis for CHIX:0QFD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:0QFD has been successfully added to your 
